Sort
21,281 grants matching “influenza”
Targeting the NS1 Protein for the Development of Influenza Virus Antivirals
$999,459Robert M Krug · University Of Texas At Austin · U01 · FY2010 · AI
Strain-Independent Therapeutic Antibodies for Influenza
$999,451Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2021 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
$999,369Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2022 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
$999,369Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2023 · AI
i-AKC: Integrated AIRR Knowledge Commons
$999,330Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2023 · AI
A Point of Care Urine Test to Aid Diagnosis of Aspergillosis
$999,316Kieren A. Marr · Pearl Diagnostics, Inc. · SB1 · FY2025 · AI
Final Preclinical Testing and Formulation of a Scalable, Live-attenuated SARS-CoV-2 Vaccine
$999,267Steffen Mueller · Codagenix, Inc. · R44 · FY2021 · AI
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
$999,234Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2024 · AI
Strain-Independent Therapeutic Antibodies for Influenza
$999,214Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2020 · AI
Human monoclonal antibodies for prevention of S. aureus infections
$999,189Gunnar Joerg Floris Kaufmann · Sorrento Therapeutics, Inc. · R42 · FY2014 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$999,032Richard A Cone · Mucommune, Llc · R44 · FY2020 · AI
Universal Influenza A/B Vaccine
$998,889Kenneth C Bagley · Orlance, Inc. · R44 · FY2023 · AI
Development of highly potent human monoclonal for RSV immuno-prophylaxis
$998,825Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2020 · AI
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2017 · HL
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
$998,663Elke Lipka · Tsrl, Inc. · R44 · FY2024 · AI
RAISE: IHBEM: Human Behavior Driven Mathematical Modeling and Forecasting of Respiratory Disease Transmission in Urban Settings
$998,658Sen Pei · Columbia University · · FY2022 · MPS
Microneedle Delivery of Zanamivir for Treatment of Influenza
$998,654Elke Lipka · Tsrl, Inc. · R44 · FY2019 · AI
Development of peptide nucleic acid antibiotics
$998,585Dev Priya Arya · Nubad, Llc · R42 · FY2024 · AI
Human monoclonal antibodies for prevention of S. aureus infections
$998,438Gunnar Joerg Floris Kaufmann · Sorrento Therapeutics, Inc. · R42 · FY2015 · AI
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
$998,375Colleen Doyle Cooper · Celdara Medical, Llc · R44 · FY2024 · AI
Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe
$997,899Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2012 · AI
Modeling the ecology of tissue-resident T cells
$997,716Andrew Yates · Columbia University Health Sciences · U01 · FY2022 · AI
Therapeutic Antibody for RSV IIB
$997,704Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2021 · AI
Improved Influenza Vaccine Efficacy Through Infection Mimicry
$997,500Kathryn Kosuda · Vaxess Technologies, Inc. · R44 · FY2020 · AI